Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and...
Samsung Biologics has extended its collaboration with LigaChem Biosciences for a...
Financing was co-led by Forbion and General Atlantic, with participants includin...
The EC has approved the extension of Stallergenes Greer’s Palforzia for the trea...
Aspect Biosystems has secured $115m in a Series B financing round to advance the...
Orbis Medicines has raised €90m ($94m) in Series A funding to advance the develo...
Sickle cell patient advocacy groups in the US are calling for greater education ...
GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adul...
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol ...
Variant has entered a multi-year research partnership with Novo Nordisk to ident...
Candid plans to conduct first-in-human studies in 2026 as it continues its T-cel...
The transaction is expected to close in the first half of 2025, subject to the s...
The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-1...
The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with...
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently i...
